Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how different treatments for toxoplasmosis—an infection that can be particularly severe in people with weakened immune systems—affect patients who are hospitalized in intensive care. The goal is to understand how these treatments work and to see if there are differences in recovery based on the patient's underlying health issues. Researchers will be looking at patients who have tested positive for toxoplasmosis and are experiencing organ failure.

To participate in this study, you must be an adult who is currently in the intensive care unit and has at least one organ that is not functioning properly. You also need to have a positive test for toxoplasmosis within a week of your ICU admission. If eligible, you can expect to be part of a study that aims to improve treatment options for future patients with this infection. It's important to note that this trial is currently recruiting participants, and your health data may be used to help researchers understand more about this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patient hospitalized in intensive care
• • At least 1 organ failure (SOFA\> or =2)
• • PCR toxoplasmosis on CSF, blood, BAL, or bone marrow positive within 7 days before or after admission to ICU
• Exclusion Criteria:
• • Post-mortem diagnosis
• • Primary outcome not available
• • Patient living informed and not opposed to the reuse of their data in this research.